Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia
The Journal of Clinical Psychiatry · 2023
DOI: 10.4088/jcp.23m14788 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift The Journal of Clinical Psychiatry, 2023. Verfasst von Oliver J Lopena und 8 weiteren Autor:innen. Beteiligte Einrichtung: Janssen Scientific Affairs, LLC, Titusville, New Jersey. Hauptthemen laut MEDLINE: Schizophrenia, Paliperidone Palmitate, Antipsychotic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref).
Abstract (Originalsprache)
Objective
To assess the efficacy and safety of paliperidone palmitate (PP) long-acting injectable antipsychotic (LAI) versus oral antipsychotic (OAP) treatment in adult patients diagnosed with schizophrenia (per DSM-IV or DSM-5 criteria) and varying duration of illness (0-3 years and > 3 years).
Methods
Patient-level data from the PRIDE, PROSIPAL, and DREaM studies were included in a post hoc analysis. Efficacy and safety outcomes, including relapse assessments, Personal and Social Performance scale scores, Medication Satisfaction Questionnaire total scores, and treatment-emergent adverse events (TEAEs), were measured systematically. Treatment failure (TF) included relapses due to psychiatric hospitalizations, arrest or incarceration, suicidal or homicidal ideation or behavior, discontinuation due to inadequate efficacy and/or safety or tolerability, treatment supplementation due to inadequate efficacy, and significant worsening of symptoms.
Results
Fewer TFs were observed with PP versus OAP in both the 0-3 years group (17.7% and 25.3%, respectively) and the > 3 years group (32.3% and 42.4%, respectively). Time to first TF was significantly longer with PP versus OAP treatment in both duration of illness groups. TEAE rates were similar between the PP and OAP groups, with no new safety signals identified.
Conclusions
This post hoc analysis suggests that PP provides significant benefit in reducing TF or relapse compared with OAPs regardless of duration of illness and highlights the potential benefit of implementing PP earlier in the course of schizophrenia. Trial Registration: ClinicalTrials.gov identifiers NCT01157351 (PRIDE), NCT01081769 (PROSIPAL), and NCT02431702 (DREaM).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Janssen Scientific Affairs, LLC, Titusville, New Jersey.
- Corresponding Author: Oliver J. Lopena, PharmD, Janssen Scientific Affairs, LLC, 1125 Trenton-Harbourton Road, Titusville, NJ 08560 (olopena@its.jnj.com).
- Drs Alphs and Starr were employees of Janssen Scientific Affairs, LLC, at the time studies were conducted.
- Neurological and Behavioral Outcomes Center, University Hospitals of Cleveland Medical Center, Case Western Reserve University School of Medicine and University Hospitals of Cleveland, Cleveland, Ohio.
- Janssen Research & Development, LLC, Titusville, New Jersey.
- Cytel, Cambridge, Massachusetts.
Zitieren
APA
Lopena, O. J., Alphs, L. D., Sajatovic, M., Turkoz, I., Sun, L., Johnston, K. L., Sliwa, J. K., Najarian, D. M., & Starr, H. L. (2023). Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia. The Journal of Clinical Psychiatry. https://doi.org/10.4088/jcp.23m14788
Vancouver
Lopena OJ, Alphs LD, Sajatovic M, Turkoz I, Sun L, Johnston KL, et al. Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia. The Journal of Clinical Psychiatry. 2023. doi:10.4088/jcp.23m14788
BibTeX
@article{Lopena2023,
author = {Lopena, Oliver J and Alphs, Larry D and Sajatovic, Martha and Turkoz, Ibrahim and Sun, Liping and Johnston, Karen L and Sliwa, Jennifer K and Najarian, Dean M and Starr, H Lynn},
title = {Earlier Use of Long-Acting Injectable Paliperidone Palmitate Versus Oral Antipsychotics in Patients With Schizophrenia},
journal = {The Journal of Clinical Psychiatry},
year = {2023},
doi = {10.4088/jcp.23m14788}
}
EUVIMED